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Abstract: OBJECTIVES Calculation of accurate T1 relaxivity (r1) values for gadolinium-based magnetic
resonance contrast agents (GBCAs) is a complex process. As such, often referenced r1 values for the
GBCAs at 1.5 T, 3 T, and 7 T are based on measurements obtained in media that are not clinically
relevant, derived from only a small number of concentrations, or available for only a limited number of
GBCAs. This study derives the r1 values of the 8 commercially available GBCAs in human whole blood
at 1.5 T, 3 T, and 7 T. MATERIALS AND METHODS Eight GBCAs were serially diluted in human
whole blood, at 7 concentrations from 0.0625 to 4 mM. A custom-built phantom held the dilutions in
air-tight cylindrical tubes maintained at 37 ± 0.5°C by a heat-circulating system. Images were acquired
using inversion recovery sequences with inversion times from 30 milliseconds to 10 seconds at 1.5 T and 3
T as well as 60 milliseconds to 5 seconds at 7 T. A custom MATLAB program was used to automate signal
intensity measurements from the images acquired of the phantom. SigmaPlot was used to calculate T1
relaxation times and, finally, r1. RESULTS Measured r1 values in units of s[BULLET OPERATOR]mM
at 1.5 T (3 T/7 T) were 3.9 ± 0.2 (3.4 ± 0.4/2.8 ± 0.4) for Gd-DOTA, 4.6 ± 0.2 (4.5 ± 0.3/4.2 ±
0.3) for Gd-DO3A-butrol, 4.3 ± 0.4 (3.8 ± 0.2/3.1 ± 0.4) for Gd-DTPA, 6.2 ± 0.5 (5.4 ± 0.3/4.7 ±
0.1) for Gd-BOPTA, 4.5 ± 0.1 (3.9 ± 0.2/3.7 ± 0.2) for Gd-DTPA-BMA, 4.4 ± 0.2 (4.2 ± 0.2/4.3 ±
0.2) for Gd-DTPA-BMEA, 7.2 ± 0.2 (5.5 ± 0.3/4.9 ± 0.1) for Gd-EOB-DTPA, and 4.4 ± 0.6 (3.5 ±
0.6/3.4 ± 0.1) for Gd-HP-DO3A. The agents can be stratified by relaxivity, with a significant additional
dependency on field strength. CONCLUSIONS This report quantifies, for the first time, T1 relaxivity for
all 8 gadolinium chelates in common clinical use worldwide, at current relevant field strengths, in human
whole blood at physiological temperature (37°C). The measured r1 values differ to a small degree from
previously published values, where such comparisons exist, with the current r1 measurements being that
most relevant to clinical practice. The macrocyclic agents, with the exception of Gd-DO3A-butrol, have
slightly lower r1 values when compared with the 2 much less stable linear agents, Gd-DTPA-BMA and
Gd-DTPA-BMEA. The 2 agents with hepatobiliary excretion, Gd-EOB-DTPA and Gd-BOPTA, have,
at 1.5 and 3 T, substantially higher r1 values than all other agents.
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T1 Relaxivities of Gadolinium-Based Magnetic Resonance
Contrast Agents in Human Whole Blood at 1.5, 3, and 7 T
Yaqi Shen, MD, PhD,* Frank L. Goerner, PhD,†‡§ Christopher Snyder, BS,† John N. Morelli, MD,k
Dapeng Hao, MD,¶ Daoyu Hu, MD,* Xiaoming Li, MD,* and Val M. Runge, MD#
Objectives: Calculation of accurate T1 relaxivity (r1) values for gadolinium-
based magnetic resonance contrast agents (GBCAs) is a complex process. As
such, often referenced r1 values for the GBCAs at 1.5 T, 3 T, and 7 T are based
on measurements obtained in media that are not clinically relevant, derived from
only a small number of concentrations, or available for only a limited number of
GBCAs. This study derives the r1 values of the 8 commercially available GBCAs
in human whole blood at 1.5 T, 3 T, and 7 T.
Materials and Methods: Eight GBCAs were serially diluted in human whole
blood, at 7 concentrations from 0.0625 to 4 mM. A custom-built phantom held
the dilutions in air-tight cylindrical tubes maintained at 37 ± 0.5°C by a heat-
circulating system. Images were acquired using inversion recovery sequences
with inversion times from 30 milliseconds to 10 seconds at 1.5 T and 3 T as well
as 60 milliseconds to 5 seconds at 7 T. A customMATLAB programwas used to
automate signal intensity measurements from the images acquired of the phan-
tom. SigmaPlot was used to calculate T1 relaxation times and, finally, r1.
Results:Measured r1 values in units of s
−1∙mM−1 at 1.5 T (3 T/7 T) were
3.9 ± 0.2 (3.4 ± 0.4/2.8 ± 0.4) for Gd-DOTA, 4.6 ± 0.2 (4.5 ± 0.3/4.2 ± 0.3)
for Gd-DO3A-butrol, 4.3 ± 0.4 (3.8 ± 0.2/3.1 ± 0.4) for Gd-DTPA, 6.2 ± 0.5
(5.4 ± 0.3/4.7 ± 0.1) for Gd-BOPTA, 4.5 ± 0.1 (3.9 ± 0.2/3.7 ± 0.2) for Gd-
DTPA-BMA, 4.4 ± 0.2 (4.2 ± 0.2/4.3 ± 0.2) for Gd-DTPA-BMEA, 7.2 ± 0.2
(5.5 ± 0.3/4.9 ± 0.1) for Gd-EOB-DTPA, and 4.4 ± 0.6 (3.5 ± 0.6/3.4 ± 0.1)
for Gd-HP-DO3A. The agents can be stratified by relaxivity, with a significant
additional dependency on field strength.
Conclusions: This report quantifies, for the first time, T1 relaxivity for all 8 gad-
olinium chelates in common clinical use worldwide, at current relevant field
strengths, in human whole blood at physiological temperature (37°C). The mea-
sured r1 values differ to a small degree from previously published values, where
such comparisons exist, with the current r1 measurements being that most rele-
vant to clinical practice. The macrocyclic agents, with the exception of Gd-
DO3A-butrol, have slightly lower r1 values when compared with the 2 much less
stable linear agents, Gd-DTPA-BMA and Gd-DTPA-BMEA. The 2 agents with
hepatobiliary excretion, Gd-EOB-DTPA and Gd-BOPTA, have, at 1.5 and 3 T,
substantially higher r1 values than all other agents.
Key Words: relaxivity, MRI contrast media, gadolinium, whole blood,
field strength dependence, 1.5 T, 3 T, 7 T, comparative studies
(Invest Radiol 2015;00: 00–00)
G adopentetate dimeglumine (Magnevist, Gd-DTPA) was thefirst gadolinium (Gd)-based magnetic resonance (MR) contrast
agent (GBCA) approved for clinical use, which occurred in 1988.
To date, 9 GBCAs have been approved for use in Europe and the
United States.1,2 The additional 8 include Gd-BOPTA (gadobenate
dimeglumine, MultiHance), Gd-DO3A-Butrol (gadobutrol, Gadovist/
Gadavist), Gd-DOTA (gadoterate meglumine, Dotarem), Gd-DTPA-
BMA (gadodiamide, Omniscan), Gd-DTPA-BMEA (gadoversetamide,
OptiMARK), Gd-EOB-DTPA (gadoxetic acid disodium, Primovist/
Eovist), Gd-HP-DO3A (gadoteridol, ProHance), andMS-325 (gadofosveset
trisodium, Ablavar). In clinical practice, the GBCAs are most com-
monly used to improve detection and differentiation of pathological le-
sions and to visualize the vasculature in MR angiography applications.
Relaxivity is a critical parameter in determining the relative effi-
cacy of the GBCAs. Relaxivity is defined as the change in reciprocal re-
laxation time per unit concentration of Gd chelate. T1 relaxivity, known
as r1, is influenced bymany variables including magnetic field strength,
temperature, environmental conditions, and protein concentration.1,3–5
Previous in vitro studies have examined the relative relaxivities
of the Gd chelates. However, these have been incomplete (not including
all relevant field strengths or deriving calculations from awide range of
concentrations), inapplicable to human imaging (not performed in hu-
man whole blood at physiologic temperatures), or failing to account
for nonlinear 1/T1 vs [Gd] when proteins are present for the protein-
binding agents.3,4,6–10 This study aimed to address these limitations
by determining the T1 relaxivity values across a wide range of concen-
trations at 1.5 T, 3 T, and 7 T for the 8 primary, commercially available
GBCAs (excluding MS-325, which is strongly protein bound, seldom
used in clinical work in most of the world, and no longer commercially
available in Europe) in human whole blood at 37°C.
MATERIALS AND METHODS
Preparation of Human Whole Blood Samples
Whole human blood was acquired from a commercial supplier
(Valley Biomedical Products & Services, Inc). Owing to 7 T scanners
not being widely available, the experiments were performed at 2 different
sites: one housing the 1.5 and 3 T scanners (site 1) and the other housing
the 7 T scanner (site 2). This also required a different human blood sam-
ple to be used at each respective site because it was not possible to pre-
serve the first sample set for use at the second site. For standardization
purposes, hematocrit fractions (Hct) of each sample set were measured
before dilution (site 1: Hct was 50 ± 0.5; site 2: Hct was 45 ± 0.5). To en-
sure that relaxivity results were not affected by the different Hct concen-
trations within the 2 different sample sets, measurements at 3 T, further
described below, were performed on each sample set. After the Hct mea-
surement, 8 commercially available GBCAs (Table 1) were serially di-
luted in human whole blood (Valley Biomedical Products & Services,
Inc). The metal concentration of Gd in the same bottles that were
used for dilution was verified using the inductively coupled plasma opti-
cal emission spectrometer (ICP-OES) technique (PerkinElmer, mod.
OPTIMA 2100 DV) after all experiments were completed (Table 2).
The ICP-OES was performed with a wavelength of observation of
342.247 nm, and the measurements were based on a calibration curve
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acquired between 0.2 and 5.0 μg/mL. Each GBCA sample was
measured 3 times independently at different dilution factors. The
ICP-OES system settings were as follows: axial view, internal standard
Rh 343.489 nm; 1300W, Neb 0.7, Aux 0.2, Myramist nebulizer, Quartz
cyclonic, Al2O3 injector.
An initial preliminary experiment demonstrated that the presence
of citrate did not affect GBCA relaxation times; thus, the specimens were
diluted with sodium citrate added as an anticoagulant. Samples were
stored at 4 ± 0.05°C until the day of scan. The half-life of human serum
is approximately 20 days; thus, all measurements were performed less
than 10 days within preparation of the whole blood samples.
All solutions were placed into glass NMR tubes (5.5  0.5 cm;
Wilmad-Lab Glass Company). Both ends were sealed with silicone to
prevent evaporation, leakage, and contamination. Each tube was used
only once and was disposed of at the end of the measurement. The sam-
ples were serially diluted with GBCA to achieve final concentrations
of 0, 0.0625, 0.125, 0.25, 0.5, 1, 2, and 4 mM GBCA at pH = 7.4 ± 0.05.
The samples were then loaded into the subsequently described phantom
and scanned at 1.5 T, 3 T, and 7 T. To minimize the error due to sedi-
mentation of red blood cells, all the tubes were gently agitated before
and during the MR image acquisitions.
Properties of the samples used for 1.5 and 3 T measurements at
site 1 were as follows: total protein concentration of 6.5 ± 0.05 g·dL−1,
albumin of 4.3 ± 0.05 g·dL−1, and Hct of 50 ± 0.5. Properties of the
samples used for 7 T measurements at site 2 were as follows: total pro-
tein concentration of 6.3 ± 0.05 g·.dL−1, albumin of 4.2 ± 0.05 g·dL−1,
and Hct of 45 ± 0.5.
For quality control purposes, subsets of each of the 2 sample sets
were imaged on a 3 T scanner and the results were compared. Concen-
trations used for these subset quality control measurements were from
0.25 to 4 mM.
Custom-Built Relaxivity Phantom
All the tubes were placed parallel in a custom-designed acrylic
holder in which 3 plastic screws were used to sandwich the tubes, hold-
ing them in place between 2 plastic plates (Fig. 1). Each holder
contained 2 sets of GBCAs (0.0625–4 mM) and a tube without any
GBCA as a control. The holder was put in the center of an air-tight cy-
lindrical acrylic container with a removable cap. The container was
equipped with 2 equal-sized flanges to allow for water to flow in and
out as well as an additional small hole in which a fiber optic probe
for temperature measurement was inserted (site 1: Essential, In vivo,
FL; site 2: Fluoroptic temperature probe, LumaSense Technologies,
CA). To control temperature, plastic tubing was attached to the flanges.
The tubing was then connected to a hot water bath (Cole-Parmer Com-
pany, IL). This allowed for warm water to flow in and out of the phan-
tom. The water exchange inside the phantom was manually controlled
to maintain a narrow temperature range for the samples (37 ± 0.5°C).
During scan acquisition, the water only circulated outside the phantom
to avoid artifacts from the motion of water.
Imaging Protocol
Measurements were performed at 1.5 T (Avanto; Siemens
Healthcare, Erlangen, Germany) on a clinical whole-body MR scanner
with an 8-channel knee coil for signal acquisition, a 3 T (Skyra;
Siemens Healthcare, Erlangen, Germany) MR system with a Tx/Rx
15-channel knee coil, and a 7 T (Philips Healthcare, Cleveland, OH) pre-
clinical MR scanner with a Tx/Rx 32-channel head coil. Additional
measurements were performed at 3 T (Verio; Siemens Healthcare,
Erlangen, Germany) with a Tx/Rx 15-channel knee coil. For each mea-
surement, a single 5-mm–thick slice was obtained perpendicular to the
long axis of the tubes. The tubes were positioned parallel to B0 along the
z axis in the magnet.
The longitudinal relaxation rate constantR1 was calculated as the
inverse of T1 relaxation time. Successive inversion recovery turbo spin-
echo sequences with varying inversion times (TIs) were used to mea-
sure the longitudinal relaxation rate constant R1.
Protocol for 1.5 and 3 T
Two different protocols (with different ranges of TI and re-
petition time [TR]) aimed at evaluation of different ranges of T1 times
were used in this study. This was done to account for the large range
of T1 times of the dilutions and for the necessity of having a TR at least
3 times the expected T1.11 When looking at the results in retrospect, it
was deemed unnecessary to perform both protocols because our results
show no statistically significance difference. Nonetheless, we chose to
report results from both protocols here. The 1.5 Tand 3 T samples were
TABLE 1. Investigated Gd-Based MR Contrast Agents
Chemical Name Generic Name (INN) Trade Name Manufacturer
Gd-BOPTA Gadobenate dimeglumine MultiHance Bracco
Gd-DO3A-butrol Gadobutrol Gadovist/Gadavist Bayer HealthCare
Gd-DOTA Gadoterate meglumine Dotarem Guerbet
Gd-DTPA Gadopentetate dimeglumine Magnevist Bayer HealthCare
Gd-DTPA-BMA Gadodiamide Omniscan GE-Healthcare
Gd-DTPA-BMEA Gadoversetamide OptiMARK Covidien
Gd-EOB-DTPA Gadoxetic acid disodium Primovist/Eovist Bayer HealthCare
Gd-HP-DO3A Gadoteridol ProHance Bracco
Gd indicates gadolinium; INN, International Nonproprietary Names; MR, magnetic resonance.
TABLE 2. ICP-OES Results of Investigated Gd-Based MR Contrast
Agents
Chemical name
Formulation
(M)
ICP-OES
(M)
Percentage Variation
From Reference Value
Gd-BOPTA 0.5 0.47 ± 0.01 −5.81
Gd-DO3A-butrol 1 0.95 ± 0.03 −4.91
Gd-DOTA 0.5 0.48 ± 0.01 −4.64
Gd-DTPA 0.5 0.48 ± 0.01 −3.61
Gd-DTPA-BMA 0.5 0.49 ± 0.01 −2.33
Gd-DTPA-BMEA 0.5 0.47 ± 0.00 −5.23
Gd-EOB-DTPA 0.25 0.23 ± 0.00 −6.56
Gd-HP-DO3A 0.5 0.48 ± 0.01 −3.84
Gd indicates gadolinium; ICP-OES, inductively coupled plasma optical emis-
sion spectrometer technique; MR, magnetic resonance.
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imaged with both of the following protocols, aimed at measuring the T1
values in parentheses:
Protocol 1 (for the Assessment of T1 Values From Approximately
50 to 600 Milliseconds)
The TIs are the following: 30, 60, 90, 120, 150, 250, 400, 600,
800, 1200, 1600, 2000, 2400, 2800, and 3200 milliseconds.
The TR is 1500 milliseconds + TI.
Protocol 2 (for the Assessment of T1 Values Longer Than
600 milliseconds)
The TIs are the following: 60, 120, 250, 400, 800, 1600, 2400,
3200, 5000, 7000, and 10,000 milliseconds.
The TR is 4000 milliseconds + TI.
For both protocols, the following parameters were held constant:
echo time, 15 milliseconds (3 T)/11 milliseconds (1.5 T); matrix, 256
256; field of view, 8080 mm2; slice thickness, 5 mm; and in-plane
spatial resolution, 3.2 pixels per millimeter.
Protocol for 7 T
For 7 T, the imaging protocol was optimized for the higher field
strength. After a preliminary experiment on 2 of the 8 GBCAs, specific
TRs and TIs were chosen to cover the whole concentration range within
a reasonable scan time that allowed for temperature to be maintained as
well as to maintain image quality equivalent to that at 1.5 T and 3 T.
Protocol
The TIs are the following: 60, 80, 120, 160, 220, 350, 500, 650,
900, 1800, 3000, and 5000 milliseconds.
The TR is 3000 milliseconds + TI.
The echo time is 10 milliseconds; matrix, 320320; field of
view, 90  90 mm2; slice thickness, 5mm; and in-plane spatial resolu-
tion, 3.6 pixels per millimeter.
Calculation of Longitudinal Relaxation Rate
Constant R1
Once the images were acquired, regions of interest (ROIs) were
automatically placed using custom-designed MATLAB code to detect
the mean signal intensities (SIs) of the sample within the tubes. The code
was designed to only include pixels within the sample and to eliminate
partial volume artifact, resulting in ROIs of 100 pixels for 3 T/1.5 T
and 140 pixels for 7 T. The MATLAB code produced mean ROI mea-
surements and an image that showed the ROI placements. All images
were manually observed for proper MATLABROI placement. The ROIs
that were observed to include susceptibility artifact were then manually
placed, and this measurement was used in subsequent calculations. Since
the signal intensities were all positive, because the scans provided magni-
tude data only, the inflection point was chosen according to the best fit
curve equation (1).12 Thus, positive numbers below the inflection point
along the x axis were converted to negative. R1 values were obtained
using equation (1) and a 3-parameter curve fitting tool (Sigma Plot
12.0). After plotting SIs versus TIs, an exponential curvewas constructed
to characterize R1 and the fitting error was used to describe the uncer-
tainty of R1 (Fig. 2).
SITI ¼ A þ Be−T I R1 ð1Þ
The 7 T Philips system had a postprocessing algorithm that
scaled the pixel values of each collected MR image. This made the im-
ages unacceptable for relaxation measurements, and the raw SI values
had to be restored. Restoration was accomplished using equation (2),
FIGURE 1. Custom-built holder and phantom. All the tubes are placed parallel to each other in a custom-design acrylic holder, using plastic screws to
sandwich the tubes and hold them in place. The holder was placed in the center of phantom with a removable cap. There was 1 hole in the center in
which to place a temperature probe (*). The holder is shown in longitudinal (A) and transverse (B) views.
FIGURE 2. Analysis of data. A, Regions of interests were automatically placed by theMATLAB program, signified bywhite rings (at 3 T, TI = 60, zoomed in
the right corner). Pixels inside the rings were measured. The temperature probe is denoted by the arrow. B, Mean SI values were used to plot T1
relaxation curves. This particular example shows curves for Gd-EOB-DTPA at a concentration of 0.25 mM and 4 mM at 3 T. C, Plotting R1 against
concentration to calculate the r1 (at 3 T for Gd-EOB-DTPA).
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scale slope and intercept are Philips tags included in the Digital Imaging
and Communications in Medicine file for each image, and all the inter-
cepts were 0 in this study.
SI7T ¼ SIMatlab − InterceptScale slope ð2Þ
Calculation of Relaxivities
Relaxivity is the second-order rate constant defining the ability of
any GBCA to catalyze water proton relaxation.1
The r1 values were calculated from equation (3), where R1(c) was
the relaxation rate constant of the contrast agent at concentration C, and
R1(0) denoted the relaxation rate constant of whole blood. Respective
error bars were attached to the plot of R1 versus concentration. The
curve fit error was used to estimate the errors of r1 (Fig. 3).
r1 ¼
R1 cð Þ − R1 0ð Þ
C
ð3Þ
For 1.5 T and 3 T evaluations, measurements from 2 protocols
were used in 3 different ways to calculate r1. This was done to ensure
that we had the most accurate relaxivity values possible and to ensure
that the 2 different protocols did not significantly impact our results.
- Method 1: r1 was calculated by data gained from protocol 1 only.
- Method 2: r1 was calculated by combined data from protocol 1 and
protocol 2 (concentration range from 0.0625–0.25 mM).
- Method 3: r1 was calculated by data gained from protocol
1 over the concentration range from 0.5 to 4 mM and from pro-
tocol 2 over the concentration range from 0.0625 to 0.25 mM.
Statistical Analysis
For the concentration ranges of 0.25 to 0.0625 mM and blood-
only controls, longitudinal relaxation rate constants R1 that were cal-
culated using protocol 1 were compared with those calculated from
protocol 2 using a one-way repeat measure analysis of variance
(SigmaPlot 12.0). For those that failed in the equal variance test, test ex-
ecution ended by ranks. The longitudinal relaxation rate constant R1 of
human whole blood from site 1, which were calculated from protocol 1,
were compared with site 2 using a rank sum test (SigmaPlot 12.0).
RESULTS
Results of ICP-OES for the 8 GBCAs are shown in Table 2. All
of them were slightly lower than the label.
Comparison Between the Longitudinal Relaxation Rate
Constant R1 Calculations From the 2 Imaging Protocols
at 1.5 T and 3 T
At 1.5 T, there was no statistically significant difference seen be-
tween R1 values calculated using protocol 1 or 2 (P > 0.05) aside from a
borderline statistically significant difference found for Gd-DTPA (P =
0.049). These results are summarized in Table 3. No statistically signif-
icant differences between R1 calculations between the 2 protocols were
TABLE 3. Comparison of R1 (s
−1) of GBCAs Using the 2 Protocols at 1.5 T
Protocol 1 Protocol 2 F P
Concentration (mM) 0.25 0.125 0.0625 0.25 0.125 0.0625
Gd-BOPTA 2.53 ± 0.09 1.71 ± 0.07 1.18 ± 0.04 2.52 ± 0.06 1.65 ± 0.07 1.18 ± 0.03 2.335 0.266
Gd-DO3A-butrol 2.04 ± 0.07 1.30 ± 0.05 0.98 ± 0.05 2.01 ± 0.08 1.30 ± 0.05 1.01 ± 0.02 0.008 0.936
Gd-DOTA 1.77 ± 0.06 1.16 ± 0.05 0.93 ± 0.08 1.79 ± 0.12 1.17 ± 0.05 0.93 ± 0.03 2.133 0.282
Gd-DTPA 2.19 ± 0.06 1.43 ± 0.05 1.08 ± 0.04 2.22 ± 0.11 1.44 ± 0.08 1.11 ± 0.03 19.104 0.049
Gd-DTPA-BMA 1.91 ± 0.04 1.34 ± 0.05 1.01 ± 0.05 1.97 ± 0.07 1.34 ± 0.06 1.02 ± 0.03 2.292 0.269
Gd-DTPA-BMEA 2.06 ± 0.05 1.34 ± 0.05 0.99 ± 0.05 2.02 ± 0.05 1.34 ± 0.04 0.99 ± 0.03 0.650 0.505
Gd-EOB-DTPA 2.48 ± 0.07 1.69 ± 0.08 1.15 ± 0.05 2.42 ± 0.06 1.65 ± 0.04 1.14 ± 0.03 5.957 0.135
Gd-HP-DO3A 2.31 ± 0.06 1.70 ± 0.07 1.36 ± 0.05 2.32 ± 0.05 1.65 ± 0.07 1.34 ± 0.05 1.570 0.337
GBCAs indicates gadolinium-based magnetic resonance contrast agents.
FIGURE 3. Graph illustrating SIs versus TIs for the 2 protocols used to measure r1 relaxivity at 1.5 T and 3 T. This example is of Gd-DOTA evaluated at
a concentration of 0.0625 mM at 3 T, with protocols 1 and 2 (A) as well as at 1.5 T with protocols 1 and 2 (B).
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found for any contrast agent at 3 T (P > 0.1). These results are summa-
rized in Figure 3 and Table 4.
Comparison Between the Longitudinal Relaxation Rate
ConstantsR1 ofHumanWhole Blood at 1.5 T, 3 T, and7T
The longitudinal relaxation rate constants R1 of human whole
blood were calculated at the 3 field strengths with comparisons of the
R1 values obtained based on the protocol used. At both 1.5 and 3 T,
there were statistically significant differences in the calculated R1 based
on the protocol used (for 1.5 T, P = 0.002; for 3 T, P = 0.027). For each
site, 4 control samples were used. This is shown in Table 5 and Figure 4.
There was no statistically significant difference seen between R1 values
calculatedwith protocol 1 of humanwhole blood used in the 2 sites at 3 T.
r1 Values of the 8 Compared GBCAs
The r1 relaxivities of the 8 compared GBCAswere calculated for
the 3 methods at 1.5 and 3 T. These values are shown in Table 6 and
Figure 5. An overview of the 8 agents and their respective r1 relaxivities
at 1.5, 3, and 7 T is presented in Figure 6.
Comparison of r1 Values for the 8 GBCAs Diluted in
Human Whole Blood With Previous Results
Table 7 details the results from the present study for measure-
ment of r1 relaxivities for the 8 GBCAs alongside previous results pub-
lished in the scientific literature. On the basis of our calculated standard
deviations and the results from all 3 methods, we present the values in
Table 7 as our most accurate measurement of r1 for all GBCAs. These
results were obtained using method 2.
DISCUSSION
This study calculated the r1 relaxivities of the 8 available GBCAs
at 1.5, 3, and 7 T from 7 different concentrations in humanwhole blood at
37°C. Relaxivity values represent theGBCAs' ability to shorten T1 times.
Gadolinium-based MR contrast agents with high relaxivity values
shorten tissue T1 times more efficaciously. They are divided in terms
of their ability to bind serum proteins into the nonprotein-binding
GBCAs (Gd-DTPA, Gd-DOTA, Gd-HP-DO3A, Gd-BT-DO3A, Gd-
DTPA-BMA, and Gd-DTPA-BMEA), the weakly protein-binding
GBCAs (Gd-BOPTA, Gd-EOB-DTPA), and the strongly protein-
binding Gd agent (MS-325).13 All GBCAs approved in the United
States and Europe other than MS-325 are assessed in the present
work. In doing so, limitations of several previous studies are addressed
because variations in experimental methods result in variations in cal-
culated r1 values. Although several previous works have been performed
on this topic, none of them perform calculations in human whole
blood. In a study by Rohrer et al,8 all available MR contrast agents
were compared at 0.47 T, 1.5 T, 3 T, and 4.7 T at 37°C, but only 2 con-
centrations (0.25 and 0.5 mmol/L) were used for the calculation. Further,
MR contrast agents were diluted in water, bovine plasma, and canine
blood to measure relaxivities, rather than whole human blood. Pintaske
et al3 performed a similar comparison in human plasma and over a
wider concentration range (0.01-64 mmol/L) at 0.2 T, 1.5 T, and 3T.
However, only 3 GBCAs (Gd-DTPA, Gd-BT-DO3A, and Gd-BOPTA)
were evaluated. The study of Noebauer-Huhmann et al14 was the
first performed at 7 T. In this work, T1 relaxivity values of 8 GBCAs
commercially available in Europe at 3 T and 7 Twere compared at 37°C.
However, only 4 different concentrations were used and error estimates
were not provided.
The aforementioned previous studies have likewise not attempted
to obtain baseline T1 values of whole human blood at various field
strengths. T1 values of blood may be influenced by Hct, temperature,
pH, and oxygenation levels.9,15–19 In fact, accurate measurements of hu-
man blood T1 values are an important topic in itself because these values
are an important MR parameter for quantitative physiological and func-
tional MR measurements, such as arterial spin labeling with cerebral
TABLE 4. Comparison of R1 (s
−1) of GBCAs Using the 2 Protocols at 3 T
Protocol 1 Protocol 2 F P
Concentration (mM) 0.25 0.125 0.0625 0.25 0.125 0.0625
Gd-BOPTA 2.06 ± 0.02 1.36 ± 0.01 0.97 ± 0.03 2.33 ± 0.06 1.32 ± 0.07 0.96 ± 0.02 0.531 0.542
Gd-DO3A-butrol 1.83 ± 0.01 1.16 ± 0.03 0.84 ± 0.04 1.72 ± 0.15 1.14 ± 0.03 0.84 ± 0.05 1*
Gd-DOTA 1.61 ± 0.07 1.05 ± 0.03 0.82 ± 0.03 1.51 ± 0.06 1.03 ± 0.02 0.82 ± 0.03 2.589 0.249
Gd-DTPA 1.78 ± 0.02 1.26 ± 0.04 0.96 ± 0.02 1.75 ± 0.07 1.23 ± 0.05 0.98 ± 0.03 0.895 0.444
Gd-DTPA-BMA 1.71 ± 0.01 1.19 ± 0.03 0.91 ± 0.03 1.67 ± 0.10 1.17 ± 0.05 0.90 ± 0.02 9.318 0.093
Gd-DTPA-BMEA 1.86 ± 0.02 1.20 ± 0.03 0.86 ± 0.03 1.87 ± 0.11 1.19 ± 0.03 0.87 ± 0.03 0.0717 0.814
Gd-EOB-DTPA 2.08 ± 0.05 1.41 ± 0.03 0.92 ± 0.11 2.15 ± 0.14 1.36 ± 0.01 0.95 ± 0.03 0.153 0.733
Gd-HP-DO3A 1.75 ± 0.02 1.51 ± 0.02 1.18 ± 0.04 1.64 ± 0.10 1.51 ± 0.05 1.19 ± 0.03 0.791 0.468
*The equal variance test failed, and test execution was ended by ranks.
GBCA indicates gadolinium-based magnetic resonance contrast agents.
TABLE 5. Longitudinal Relaxation Rates R1 (s
−1) of Human Whole Blood at 37°C
1.5 T* 3 T†
7 TProtocol 1 Protocol 2 Protocol 1‡ Protocol 2
0.74 ± 0.00 0.78 ± 0.01 0.59 ± 0.05 0.56 ± 0.03§ 0.64 ± 0.05 0.44 ± 0.01§
*Comparison of the results of the 2 protocols: F = 107.824 and P = 0.002 1.5T.
†Comparison of the results of the 2 protocols: F = 16.352 and P = 0.027 3T.
‡Comparison of the results of 2 sites: t = 0.715 and P = 0.514.
§Blood of site 2.
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blood volume calculations. Previously, T1 values of bovine blood had
been measured at 1.5 T, 3 T,18 4.7 T, 7 T, and 9.4 T.17 T1 values of rat
blood have also been measured at 11.7 T.16 Human blood T1 values have
also recently been measured at 3 T19 and 7 T.15
Inversion recovery turbo spin-echo pulses have traditionally
been the standard pulse sequences by which to measure longitudinal re-
laxation rate constants (R1). In the present study, 2 protocols were used
at 1.5 T and 3 T. These protocols incorporated different T1 times on
the basis of principles outlined by Ogg and Kingsley,11 namely,
that TR should be at least 3 times longer than the T1 time. Data
points generated by plotting SI against TI with protocol 2 yielded data
points evenly distributed along the exponential curve, whereas few
data points measured with protocol 1 were distributed on the flat part
of the curve (Fig. 3). Theoretically, the data from protocol 2 should
give a more accurate depiction of relaxation curves for the lower con-
centrations, thus leading to more accurate results. Although the results
from 2 protocols were slightly different from each other, no statisti-
cally significant differences were found between them, except for
borderline statistically significant results with Gd-DTPA at 1.5 T
(Table 2). The measurements of the longitudinal relaxation rate con-
stants of human whole blood from the 2 protocols were statistically
significantly different at both 1.5 T and 3 T (Table 4). Theoretically,
the results from protocol 2 should be more accurate than those
from protocol 1 because the former gave a relaxation curve fitting
the expected exponential distribution more closely (Fig. 4). The statis-
tically significant differences in the R1 measurements for whole blood
are likely caused by the long T1 relaxation time of whole blood and
the fact that one of the protocols used a TR of 1500 milliseconds. In
the end, the difference was not large enough to impact our results. We
found no statistical difference when using results from protocol 1 or 2
when calculating relaxivity.
Only 1 protocol was used to measure whole blood longitudinal
relaxation at 7 T. The calculated T1 values of human whole blood in
the present study was in accordance with the study done by Rane et al15
(2.29 ± 0.1 seconds for human arterial blood, 2.09 ± 0.12 seconds for
human venous blood, 2.16 ± 0.1 seconds for clinic patient's venous
blood). Also, T1 values of human blood in the present study were linearly
dependent on B0, which is consistent with previous studies
15–18 (Fig. 4).
According to the literature, r1 is characterized by the change
in relaxation rate constant per unit concentration of Gd chelate and is
independent of concentration. The number of relaxation rate constant
data points collected is critical to derive accurate statistical predictions
from the regression analysis. Only 2 concentrations (0.25 and
0.50mM) were used for curve computation by Rohrer et al8; and 4 con-
centrations (0.25, 0.5, 1, and 2 mM), by Noebauer-Huhmann et al.14 In
the present study, 7 different concentrations were used. Slight differ-
ences are also found when obtaining relaxation rate constant measure-
ments with the 2 used protocols. Theoretically, R1 measured with
protocol 2 should be more accurate for lower GBCA concentrations
and protocol 1 for higher GBCA concentrations. Thus, it is reasonable
to assume that calculations that combine data obtained using the 2 dif-
ferent protocols are best used to include thewide range of concentrations
FIGURE 4. Calculation of human whole blood R1 relaxation rate constant as performed using protocol 1 (A) and 2 (B) at 1.5 T as well as protocol 1 and
2 at 3 T. Four control samples were included in the calculation. The calculated values were linearly dependent on B0 (C).
TABLE 6. Comparison of r1 (s
−1·mM−1) of GBCAs With the 2 Protocols at 1.5 T and 3 T
1.5 T 3 T
1 2 3 1 2 3
Gd-BOPTA 6.15 ± 0.38 6.20 ± 0.36 6.16 ± 0.39 5.36 ± 0.33 5.37 ± 0.33 5.33 ± 0.37
Gd-DO3A-butrol 4.58 ± 0.19 4.61 ± 0.18 4.58 ± 0.18 4.42 ± 0.26 4.46 ± 0.24 4.44 ± 0.27
Gd-DOTA 3.89 ± 0.14 3.91 ± 0.13 3.89 ± 0.14 3.40 ± 0.31 3.43 ± 0.29 3.41 ± 0.32
Gd-DTPA 4.22 ± 0.34 4.25 ± 0.32 4.21 ± 0.34 3.75 ± 0.18 3.76 ± 0.17 3.75 ± 0.19
Gd-DTPA-BMA 4.46 ± 0.09 4.47 ± 0.08 4.46 ± 0.08 3.87 ± 0.16 3.89 ± 0.15 3.88 ± 0.17
Gd-DTPA-BMEA 4.41 ± 0.19 4.43 ± 0.18 4.41 ± 0.19 4.23 ± 0.12 4.24 ± 0.12 4.23 ± 0.12
Gd-EOB-DTPA 7.24 ± 0.17 7.24 ± 0.15 7.25 ± 0.17 5.42 ± 0.27 5.45 ± 0.26 5.42 ± 0.27
Gd-HP-DO3A 4.32 ± 0.49 4.39 ± 0.47 4.32 ± 0.50 3.41 ± 0.49 3.46 ± 0.46 3.41 ± 0.51
Method 1: r1 was calculated by data gained from protocol 1 only.
Method 2: r1 was calculated by data gained from protocol 1 and protocol 2 (concentration range, 0.0625–0.25 mM).
Method 3: r1 was calculated by data gained from protocol 1 (concentration range, 0.5–4 mM) and protocol 2 (concentration range, 0.0625–0.25 mM).
GBCA indicates gadolinium-based magnetic resonance contrast agents.
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FIGURE 5. Illustrated is R1 plotted against concentration for the 8 GBCAs at 1.5 T, 3 T, and 7 T.
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present. Considering this issue, 3 different methods were used to cal-
culate r1. The results were similar for all 3 approaches (Table 6). The
calculated error (standard deviation) found from method 2 (which
incorporated combined results from protocol 1 and protocol 2) was
less than or equal to those calculated with the other methods; thus, we
present this as our most accurate results and they are shown in Table 7.
In the study of Noebauer-Huhmann et al,14 the small number of con-
centrations used for the r1 calculation adds to the uncertainty of the re-
sults. Pintaske et al3 used a wider range of concentrations (0.01, 0.02,
0.03, 0.06, 0.13, 0.25, 0.5, 1, 2, 4, 8, 16, 32, and 64 mM) in human blood
plasma, however, with only 3 GBCAs. They stated that the relationship
between R1 and concentration was nonlinear with Gd-BOPTA.
Noebauer-Huhmann et al14 determined that all 8 GBCAs had a nonlin-
ear relationship between R1 and concentration at both 3 T and 7 T. In
the present study, plots ofR1 against concentration of 8 GBCAs showed
no consistent pattern andwere not definitely linear or nonlinear (Fig. 5).
Different serum total protein and albumin in each of experimental ma-
terial setups could be the reason.20,21 Another reason for discrepancies
can be attributed to inaccuracies of concentration determination and /or
species-dependent influences of the blood plasma samples. One poten-
tial limitation of the present study is that blood oxygenation may influ-
ence blood T1 values. However, conflicting conclusions regarding
the influence of blood oxygen content have been reached in previous
studies.15–19 In the study of Lin et al,16 rat blood T1 values were found
to be independent of oxygenation. The study of Rane et al15 demon-
strated that T1 values of human blood at 7 T differed depending on
whether arterial or venous blood was examined. Other limitations in-
clude the fact that citrate was present in the blood in the present study,
as discussed previously in theMaterials andMethods section. However,
a preliminary experiment demonstrated no differences in relaxivity
values on this basis, thus justifying this approach. Also, different
sources of blood were used, a fact that was accounted for by controlling
for Hct and ensuring that serum total protein and albumin were similar.
In addition, 3 T measurements were obtained on samples of both the
blood sources to further ensure standardization. The relaxivity values
acquired at 3 T from both sites/sampleswere similar. Lower Gd concen-
tration than what was stated on the label may also have affected our
results; however, the relaxivity calculations reflect the formulation of
the agents as commercially supplied (Table 2). TA
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FIGURE 6. An overview of the 8 agents and their respective r1 relaxivities
at 1.5, 3, and 7 T is presented in a graphical format.
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The current study provides T1 relaxivity measurements, obtained
from human whole blood, comparing the 8 Gd chelates commonly used
worldwide as intravenous contrast media for magnetic resonance, at cur-
rent relevant field strengths (1.5, 3, and 7 T) and physiologic temperature.
The results from the present study should serve as a reasonable and reli-
able reference for further clinical use.
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